Email: cspc@cspc.cn
News
News Center
Jun. 30
2026
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE ADJUVANT TREATMENT OF RESECTED STAGE II-IIIB NON-SMALL CEL
Jun. 26
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF DRIVER GENE-NEGATIVE NON-SMALL CELL LUNG CANC
Jun. 18
VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION (SYHX2008) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR SECUKINUMAB INJECTION
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS SECOND MARKETING AUTHORISATION APPLICATION FOR EFMEDAGLUTIDE ALFA INJECTION
Jun. 16
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR VALSARTAN AND LEVAMLODIPINE MALEATE TABLETS (SYH9056 TABLETS)
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
